DIURNAL CHANGES IN HEPARIN EFFECT DURING CONTINUOUS CONSTANT-RATE INFUSION - A STUDY IN 9 PATIENTS WITH VENOUS THROMBOEMBOLISM

被引:20
作者
KRULDER, JWM [1 ]
VANDENBESSELAAR, AMHP [1 ]
VANDERMEER, FJM [1 ]
MEINDERS, AE [1 ]
BRIET, E [1 ]
机构
[1] LEIDEN UNIV HOSP,DEPT HAEMOSTASIS,LEIDEN,NETHERLANDS
关键词
ANTICOAGULANTS; CHRONOBIOLOGY; CIRCADIAN RHYTHM; HEPARIN; PULMONARY EMBOLISM; THROMBOSIS;
D O I
10.1111/j.1365-2796.1994.tb01096.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective, To evaluate the importance of diurnal variations in the effect of a continuous infusion of unfractionated heparin. Design. Twenty-four-hour follow-up. Setting. Tertiary referral centre. Subjects. Patients (five male, four female) with acute venous thromboembolic diseases. Main outcome measures. Two-hourly measurement of anti-IIa activity, anti-Xa activity, APTT (Cephotest and automated APTT), antithrombin III and cortisol for 24 h. Results, The maximum anticoagulant effect was found at 04.00-06.00 hours, and the minimum effect at 12.00 hours. The difference was 0.40 U ml(-1) for anti-IIa activity (95% confidence interval (CI) 0.03-0.78; P < 0.05), 0.36 U ml(-1) for anti-Xa activity (95% CI-0.05-0.72; not significant [NS]), 15.1 s for Cephotest APTT (95% CI 3.3-26.9; P < 0.03), and 112.9 s for automated APTT (95% CI 7.8-218.0; P < 0.05). Antithrombin III decreased from 97.9% at the start to 82.6% 24 h later (P = 0.001). Cortisol showed a typical diurnal rhythm. Expressed as a percentage of the individual 24-h mean, a maximum was found at 04.00 hours (anti-IIa activity), 06.00 hours (both APTTs), and 08.00 hours (anti-Xa activity) and a minimum at 12.00 hours (all variables). The difference was 26% for anti-IIa activity (P < 0.05) and anti-Xa activity (NS), 22% for APTT (Cephotest; P < 0.03), and 44% for APTT (automated APTT; P < 0.05). Conclusions. A continuous intravenous infusion of unfractionated heparin has a maximum anticoagulant effect between 04.00 and 8.00 hours and a minimum effect at noon. For individual patients the moment of minimum and maximum effect varies widely. Because the most impressive changes occur between 06.00 and 08.00 hours, laboratory control can best be performed at fixed times, e.g. at 10.00 and at 22.00 hours.
引用
收藏
页码:411 / 417
页数:7
相关论文
共 17 条
[1]   REFERENCE VALUES OF HEMOSTASIS RELATED FACTORS OF HEALTHY JAPANESE ADULTS .1. CIRCADIAN FLUCTUATION [J].
AKIYAMA, Y ;
KAZAMA, M ;
TAHARA, C ;
SHIMAZU, C ;
OTAKE, J ;
KAMEI, K ;
NAKATAKE, T ;
SAKURAI, N ;
YASUMURO, Y ;
SUZUKI, S ;
MAEBA, E ;
NISHIDA, T .
THROMBOSIS RESEARCH, 1990, 60 (04) :281-289
[2]   CIRCADIAN CHANGES IN ANTICOAGULANT EFFECT OF HEPARIN INFUSED AT A CONSTANT RATE [J].
DECOUSUS, HA ;
CROZE, M ;
LEVI, FA ;
JAUBERT, JG ;
PERPOINT, BM ;
DEBONADONA, JF ;
REINBERG, A ;
QUENEAU, PM .
BMJ-BRITISH MEDICAL JOURNAL, 1985, 290 (6465) :341-344
[3]   NYCTHEMERAL VARIATIONS OF TC-99M-LABELLED HEPARIN PHARMACOKINETIC PARAMETERS [J].
DECOUSUS, M ;
GREMILLET, E ;
DECOUSUS, H ;
CHAMPAILLER, A ;
HOUZARD, C ;
PERPOINT, B ;
JAUBERT, J .
NUCLEAR MEDICINE COMMUNICATIONS, 1985, 6 (10) :633-640
[4]   CHANGES OF ACTIVATED PARTIAL THROMBOPLASTIN TIME DURING CONSTANT INTRAVENOUS AND FIXED INTERMITTENT SUBCUTANEOUS ADMINISTRATION OF HEPARIN [J].
FAGRELL, B ;
ARVER, S ;
INTAGLIETTA, M ;
TSAI, AG .
JOURNAL OF INTERNAL MEDICINE, 1989, 225 (04) :257-260
[5]   CIRCADIAN VARIATIONS IN BLOOD-COAGULATION PARAMETERS, ALPHA-ANTITRYPSIN ANTIGEN AND PLATELET-AGGREGATION AND RETENTION IN CLINICALLY HEALTHY-SUBJECTS [J].
HAUS, E ;
CUSULOS, M ;
SACKETTLUNDEEN, L ;
SWOYER, J .
CHRONOBIOLOGY INTERNATIONAL, 1990, 7 (03) :203-216
[6]   CORTISOL IS SECRETED EPISODICALLY BY NORMAL MAN [J].
HELLMAN, L ;
NAKADA, F ;
CURTI, J ;
WEITZMAN, ED ;
KREAM, J ;
ROFFWARG, H ;
ELLMAN, S ;
FUKUSHIM.DK ;
GALLAGHE.TF .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1970, 30 (04) :411-+
[7]   OBSERVATION OF HEPARIN ON ENDOTHELIUM AFTER INJECTION [J].
HIEBERT, LM ;
JAQUES, LB .
THROMBOSIS RESEARCH, 1976, 8 (02) :195-204
[8]   ANTITHROMBOTIC THERAPY IN DEEP-VEIN THROMBOSIS AND PULMONARY-EMBOLISM [J].
HIRSH, J .
AMERICAN HEART JOURNAL, 1992, 123 (04) :1115-1122
[9]   OPTIMAL THERAPEUTIC LEVEL OF HEPARIN-THERAPY IN PATIENTS WITH VENOUS THROMBOSIS [J].
HULL, RD ;
RASKOB, GE ;
ROSENBLOOM, D ;
LEMAIRE, J ;
PINEO, GF ;
BAYLIS, B ;
GINSBERG, JS ;
PANJU, AA ;
BRILLEDWARDS, P ;
BRANT, R .
ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (08) :1589-1595
[10]  
KRULDER JWM, 1992, THROMB HAEMOSTASIS, V68, P30